Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

RxSight (RXST) Accumulated Expenses (2020 - 2025)

RxSight (RXST) has disclosed Accumulated Expenses for 6 consecutive years, with $19.8 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Accumulated Expenses fell 2.77% year-over-year to $19.8 million, compared with a TTM value of $19.8 million through Dec 2025, down 2.77%, and an annual FY2025 reading of $19.8 million, down 2.77% over the prior year.
  • Accumulated Expenses was $19.8 million for Q4 2025 at RxSight, up from $17.6 million in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $20.4 million in Q4 2024 and bottomed at $4.8 million in Q2 2021.
  • Average Accumulated Expenses over 5 years is $12.4 million, with a median of $12.7 million recorded in 2022.
  • The sharpest move saw Accumulated Expenses soared 88.28% in 2021, then fell 2.77% in 2025.
  • Year by year, Accumulated Expenses stood at $7.9 million in 2021, then surged by 61.24% to $12.7 million in 2022, then rose by 20.26% to $15.2 million in 2023, then surged by 33.59% to $20.4 million in 2024, then decreased by 2.77% to $19.8 million in 2025.
  • Business Quant data shows Accumulated Expenses for RXST at $19.8 million in Q4 2025, $17.6 million in Q3 2025, and $15.9 million in Q2 2025.